Post-azacitidine, TTCR-C4 counts increased (~50 multimer+ CD8+ T cells/ul; >3% CD8 multimer+ T cells) without additional TTCR-C4 (Fig. 6D), leading to azacitidine discontinuation after seven cycles when no AML was detected. This evidence concerns the gene CD8A and acute myeloid leukemia.